- Home
- MRSN vs OTLK Comparison
MRSN vs OTLK Comparison
Compare MRSN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- OTLK
- Stock Information
- Founded
- MRSN 2001
- OTLK 2010
- Country
- MRSN United States
- OTLK United States
- Employees
- MRSN N/A
- OTLK N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRSN Health Care
- OTLK Health Care
- Exchange
- MRSN Nasdaq
- OTLK Nasdaq
- Market Cap
- MRSN 40.7M
- OTLK 48.3M
- IPO Year
- MRSN 2017
- OTLK 2016
- Fundamental
- Price
- MRSN $0.29
- OTLK $1.76
- Analyst Decision
- MRSN Strong Buy
- OTLK Strong Buy
- Analyst Count
- MRSN 5
- OTLK 5
- Target Price
- MRSN $5.75
- OTLK $9.60
- AVG Volume (30 Days)
- MRSN 2.8M
- OTLK 792.9K
- Earning Date
- MRSN 08-12-2025
- OTLK 08-13-2025
- Dividend Yield
- MRSN N/A
- OTLK N/A
- EPS Growth
- MRSN N/A
- OTLK N/A
- EPS
- MRSN N/A
- OTLK 0.83
- Revenue
- MRSN $34,006,000.00
- OTLK N/A
- Revenue This Year
- MRSN N/A
- OTLK N/A
- Revenue Next Year
- MRSN $1.30
- OTLK $379.84
- P/E Ratio
- MRSN N/A
- OTLK $2.15
- Revenue Growth
- MRSN N/A
- OTLK N/A
- 52 Week Low
- MRSN $0.26
- OTLK $0.87
- 52 Week High
- MRSN $2.83
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- MRSN 38.23
- OTLK 52.03
- Support Level
- MRSN $0.27
- OTLK $1.56
- Resistance Level
- MRSN $0.36
- OTLK $1.75
- Average True Range (ATR)
- MRSN 0.03
- OTLK 0.12
- MACD
- MRSN -0.01
- OTLK -0.01
- Stochastic Oscillator
- MRSN 16.81
- OTLK 38.14
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.